Cargando…

Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) arises in a cirrhotic, pro-angiogenic microenvironment. Inhibiting angiogenesis is a key mode of action of multikinase inhibitors and current non-cirrhotic models are unable to predict treatment response. We present a novel mouse cirrhotic model...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Daniel Q., Muthiah, Mark D., Zhou, Lei, Jumat, Halisah, Tan, Wan Xin, Lee, Guan Huei, Lim, Seng Gee, Kow, Alfred, Bonney, Glenn, Shridhar, Iyer, Lim, Yi Ting, Wee, Aileen, Pang, Yin Huei, Soon, Gwyneth, Chow, Pierce, Dan, Yock Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020437/ https://www.ncbi.nlm.nih.gov/pubmed/33340714 http://dx.doi.org/10.1016/j.jcmgh.2020.12.009

Ejemplares similares

A murine model demonstrating reversal of structural and functional correlates of cirrhosis with progenitor cell transplantation
por: Muthiah, Mark D., et al.
Publicado: (2019)

Comparable Outcomes in Early Hepatocellular Carcinomas Treated with Trans-Arterial Chemoembolization and Radiofrequency Ablation
por: Tay, Benjamin Wei Rong, et al.
Publicado: (2022)

Evaluation of fibrosis in cirrhotic elderly patients with HCC
por: Pesce, A, et al.
Publicado: (2011)

In silico analysis excavates potential biomarkers by constructing miRNA-mRNA networks between non-cirrhotic HCC and cirrhotic HCC
por: Ding, Bisha, et al.
Publicado: (2019)

A Multiethnic Asian Perspective of Presumed Consent for Organ Donation: A Population-Based Perception Study
por: Muthiah, Mark D., et al.
Publicado: (2021)

A 2015 roadmap for the management of hepatitis C virus infections in Asia
por: Lim, Seng Gee, et al.
Publicado: (2015)

Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy
por: Zhao, Yue, et al.
Publicado: (2018)

Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population
por: Lee, Guan Huei, et al.
Publicado: (2020)

Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors
por: Lim, Jhin Jieh, et al.
Publicado: (2022)

Acute-on-chronic liver failure in a multi-ethnic Asian city: A comparison of patients identified by Asia-Pacific Association for the Study of the Liver and European Association for the Study of the Liver definitions
por: Selva Rajoo, Anandraj, et al.
Publicado: (2017)

Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver
por: Schütte, Kerstin, et al.
Publicado: (2014)

Risk factors for ribavirin treatment failure in Asian organ transplant recipients with chronic hepatitis E infection
por: Low, En Xian Sarah, et al.
Publicado: (2019)

A study of 3013 cases of hepatocellular carcinoma: Etiology and therapy before and during the current decade
por: Lim, Miao‐Shan, et al.
Publicado: (2021)

Safely Implementing a Program of Pure Laparoscopic Donor Right Hepatectomy: The Experience From a Southeast Asian Center
por: Law, Jia-Hao, et al.
Publicado: (2023)

Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC
por: Sydor, Svenja, et al.
Publicado: (2020)

Interleukin-6: A New Marker of Advanced-Sarcopenic HCC Cirrhotic Patients
por: Dalbeni, Andrea, et al.
Publicado: (2023)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018)

Trajectory of immune evasion and cancer progression in hepatocellular carcinoma
por: Nguyen, Phuong H. D., et al.
Publicado: (2022)

Regional Ischemic Preconditioning Has Clinical Value in Cirrhotic HCC Through MAPK Pathways
por: Wang, Liming, et al.
Publicado: (2018)

Author Correction: Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma
por: Nguyen, Phuong H. D., et al.
Publicado: (2021)

Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
por: Soon, Gwyneth, et al.
Publicado: (2021)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Inositol polyphosphate multikinase signaling in the regulation of metabolism
por: Lee, Joo-Young, et al.
Publicado: (2012)

Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014)

Daily Management of Patients on Multikinase Inhibitors’ Treatment
por: Colombo, Carla, et al.
Publicado: (2022)

Deal a death blow! HCC in cirrhotics – thrombotic complications: their frequency, characteristics, and risk factors
por: Mahmood, Khalid, et al.
Publicado: (2018)

Predictive and Prognostic Roles of Gut Microbial Variation in Liver Transplant
por: Wong, Hon Jen, et al.
Publicado: (2022)

Emerging role of multikinase inhibitors for refractory thyroid cancer
por: Perez, Cesar A, et al.
Publicado: (2012)

Exploring Selectivity of Multikinase Inhibitors across the Human Kinome
por: Miljković, Filip, et al.
Publicado: (2018)

Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
por: Lin, Tong, et al.
Publicado: (2017)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Timing of multikinase inhibitor initiation in differentiated thyroid cancer
por: Brose, Marcia S, et al.
Publicado: (2017)

Gastrointestinal Tract Homeostasis: The Role of the Inositol Polyphosphate Multikinase
por: Saiardi, Adolfo
Publicado: (2022)

Histone‐lysine N‐methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc‐driven liver cancer
por: Thng, Dexter Kai Hao, et al.
Publicado: (2023)

Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians
por: Chanyaputhipong, Jendana, et al.
Publicado: (2011)

Splice‐switch oligonucleotide‐based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC‐driven hepatocellular carcinoma
por: Thng, Dexter Kai Hao, et al.
Publicado: (2022)

Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere?
por: Tan, Chun Han Nigel, et al.
Publicado: (2018)

Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC
por: SALVI, ALESSANDRO, et al.
Publicado: (2012)

One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment
por: Tseng, Tai-Chung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_537nlapo366kqagho3m04t3lpn